Last reviewed · How we verify

BBV154(Intranasal) & covaxin — Competitive Intelligence Brief

BBV154(Intranasal) & covaxin (BBV154(Intranasal) & covaxin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viral vector vaccine. Area: Immunology / Infectious Disease.

phase 3 Viral vector vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

BBV154(Intranasal) & covaxin (BBV154(Intranasal) & covaxin) — Bharat Biotech International Limited. BBV154 is an intranasal booster vaccine designed to enhance immune response against SARS-CoV-2 when administered after Covaxin (inactivated COVID-19 vaccine) priming.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BBV154(Intranasal) & covaxin TARGET BBV154(Intranasal) & covaxin Bharat Biotech International Limited phase 3 Viral vector vaccine SARS-CoV-2 spike protein
COMIRNATY - BioNTech Manufacturing GmbH COMIRNATY - BioNTech Manufacturing GmbH Jens D Lundgren, MD marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
Comirnaty Omicron XBB.1.5 Comirnaty Omicron XBB.1.5 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (XBB.1.5 variant)
Comirnaty Original/Omicron BA.1 Comirnaty Original/Omicron BA.1 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
Regeneron Casirivimab + Imdevimab Regeneron Casirivimab + Imdevimab Erin McCreary marketed Monoclonal antibody combination (neutralizing antibodies) SARS-CoV-2 spike protein
Lilly Bamlanivimab + Etesevimab Lilly Bamlanivimab + Etesevimab Erin McCreary marketed Monoclonal antibody combination (neutralizing antibodies) SARS-CoV-2 spike protein receptor-binding domain
Intramuscularly administered Ad5-nCoV vaccine Intramuscularly administered Ad5-nCoV vaccine Jiangsu Province Centers for Disease Control and Prevention marketed viral vector vaccine SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viral vector vaccine class)

  1. Janssen Vaccines & Prevention B.V. · 5 drugs in this class
  2. University of Oxford · 3 drugs in this class
  3. Crucell Holland BV · 3 drugs in this class
  4. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
  5. Bharat Biotech International Limited · 2 drugs in this class
  6. Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 drug in this class
  7. London School of Hygiene and Tropical Medicine · 1 drug in this class
  8. Samia Hassan El-Shishtawy · 1 drug in this class
  9. University Medicine Greifswald · 1 drug in this class
  10. Aeras · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BBV154(Intranasal) & covaxin — Competitive Intelligence Brief. https://druglandscape.com/ci/bbv154-intranasal-covaxin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: